MarketInOut Stock Screener Log In | Sign Up
 

Ascendis Pharma A/S

NASDAQ • Healthcare • Biotechnology • Quote as of 10/16/2026 16:00
Ascendis Pharma A/S stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization14,840 mln
Float64.91 mln
Earnings Date11/11/2026

EPS

13.05
Robust

P / E

17.26
Moderately valued

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

2.7
Highly suspicious

1-Year Forecast

305.64
Strong upside

Relative Strength

53 / 100
Slightly ahead

Business Description

Founded in Denmark in 2006, Ascendis Pharma is a drug development company built around its proprietary TransCon technology, which is designed to improve how medicines work in the body. The company currently sells two approved treatments ? one for children with growth hormone deficiency and another for adults with a rare condition affecting calcium regulation. Beyond these products, Ascendis is advancing additional treatments for rare hormonal disorders and exploring new therapies in cancer care.

Key Fundamentals

EPS13.05
P/E17.26
ROE277
RPS18.23
ROIC8.39
ROA48.50
Interest Cover0.51
EBITDA, mln394
EV / EBITDA38.73
EV / EBIT40.87
Revenue, mln1,221
EV / Revenue12.50

Quote Details

Last 225.25
Change -1.37 (-0.6%)
Open 226.62
Volume 680,312
Turnover 153,240,272
Average Volume 817,472

Financial Ratios

Pre-Tax Profit Margin10
Leverage Ratio1.59
Current Ratio2.99
Price / Book9.11
Price / Tangible Book9.14
Price / Cash Flow37.08
Price / Free Cash Flow39.22
Debt / Equity0.31
Price / Sales11.99
PEG Ratio0.83

Financial Strength

Altman Z-Score9.53
Piotroski F-Score 7 / 9
Beneish M-Score2.7
Price to Graham Number2.65
1-Year Target Price305.64
Short Ratio3.87
Short % of Float6.27

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.74% 49 / 100   
1 Month -5.77% 36 / 100   
2 Months -15.07% 27 / 100   
6 Months -7.87% 37 / 100   
1 Year 8.75% 64 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us